Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.25    1.10 (14.86%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £59.93m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

Form 8.5 Poolbeg Pharma Plc

14 Feb 2025 09:11

RNS Number : 1900X
J & E Davy (UK) Limited
14 February 2025
 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J&E Davy (UK) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Poolbeg Pharma PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

Poolbeg Pharma PLC

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

13/02/2025

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Poolbeg Pharma PLC Ordinary 0.02p

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

209,416

0.04

NA

NA

(2) Cash-settled derivatives:

 

N/A

N/A

N/A

N/A

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

N/A

N/A

N/A

N/A

 

209,416

0.04

NA

NA

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Poolbeg Pharma PLC Ordinary 0.02p

 

Purchase

40,240

5.00 GBX

5.00 GBX

Poolbeg Pharma PLC Ordinary 0.02p

 

Sale

-

-

-

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

N/A

N/A

 

N/A

N/A

N/A

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

N/A

N/A

N/A

N/A

N/A

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

None

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

14/02/2025

Contact name:

Zaid Ahmad

Telephone number:

016142867

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEOGCGDDIGBDGUS
Date   Source Headline
26th May 20267:00 amRNSPre-IND Meeting with the FDA for POLB 001
13th May 20267:00 amRNSPOLB 001 poster to be presented at EHA 2026
11th May 20267:00 amRNSPOLB 001 CRS patent granted in Canada
7th May 20267:00 amRNSAnnual Report & AGM Notice
28th Apr 20267:00 amRNSResults for the year ended 31 December 2025
15th Apr 20267:00 amRNSMHRA grants CTA for the POLB 001 TOPICAL trial
31st Mar 20267:00 amRNSSignificant milestone for Poolbeg's IP portfolio
12th Mar 20267:00 amRNS-RAppointment of Dr Adrian Kilcoyne to SAB
9th Feb 20263:13 pmRNSNotification of Major Holdings
28th Jan 20267:00 amRNSPOLB 001 LPS Challenge Trial Paper Published
27th Jan 20262:30 pmRNSExercise of Options & Total Voting Rights
18th Dec 20257:00 amRNS-RLetter to Shareholders – 2025 a year of progress
8th Dec 20257:00 amRNS-RPOLB 001 to feature in CRS research programme
20th Nov 20257:00 amRNSPOLB 001 European Patent granted
29th Sep 20257:00 amRNSInterim Results for the six months to 30 June 2025
25th Sep 20257:00 amRNSPOLB 001 Phase 2a Trial Update
1st Jul 20254:24 pmRNSNotification of Major Holdings
26th Jun 20257:00 amRNSNotification of Major Holdings
25th Jun 20258:00 amRNSDirector/PDMR Shareholding
23rd Jun 20252:57 pmRNSResults of GM and AGM Meetings
27th May 20257:01 amRNSFDA Orphan Drug Designation granted for POLB 001
27th May 20257:00 amRNSAnnual Report, AGM Notice & Circular
23rd May 20257:00 amRNSResult of upsized oversubscribed BookBuild Offer
22nd May 20251:44 pmRNSIncrease of BookBuild Offer
20th May 202512:26 pmRNSResult of Placing and Notice of General Meeting
20th May 20257:02 amRNSProposed Retail Offer to raise up to £100,000
20th May 20257:01 amRNSProposed Fundraising to raise approximately £4.1M
20th May 20257:00 amRNSResults for the year ended 31 December 2024
27th Mar 20257:00 amRNS-RConference Participation in March & April 2025
20th Mar 20257:00 amRNS-RPOLB 001 Patent Granted in Korea
25th Feb 20258:50 amRNSForm 8.5 (EPT/NON-RI)
24th Feb 20258:48 amRNSForm 8.5 (EPT/NON-RI)
21st Feb 202511:53 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
21st Feb 20257:00 amRNSTermination of proposed combination with HOOKIPA
20th Feb 20258:06 pmGNWHOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
20th Feb 20259:03 amRNSForm 8.5 Poolbeg Pharma Plc
20th Feb 20258:53 amRNSForm 8.5 (EPT/NON-RI)
20th Feb 20257:49 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
19th Feb 202512:35 pmGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
18th Feb 20255:35 pmRNSHolding(s) in Company
18th Feb 20255:04 pmRNSForm 8.3 - Poolbeg Pharma plc
18th Feb 202510:17 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
17th Feb 202510:28 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
14th Feb 202510:25 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
14th Feb 20259:11 amRNSForm 8.5 Poolbeg Pharma Plc
13th Feb 202511:17 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
13th Feb 202510:30 amRNSForm 8.5 Poolbeg Pharma Plc
12th Feb 202510:52 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
12th Feb 20259:08 amRNSForm 8.5 Poolbeg Pharma Plc
11th Feb 20259:46 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.